Chinese CAR-M Leader Yuanmai Cell Therapeutics Secures Pre-A Funding and Advances Clinical Pipeline

Recently, Macera Therapeutics successfully completed its Pre-A financing round, which was jointly invested by the Taizhou Angel Investment Fund and Nanjing Chuangyi Dingxin Venture Capital Partnership.

Since its establishment, Macera Therapeutics has continuously attracted significant capital market backing. The company has successfully completed its angel funding round, securing strategic investments from prominent institutions including CDH Investments, Renai Group, and Nanjing Innovation Investment Group. Furthermore, two angel funds under the Jiangsu Province Strategic Emerging Industry Fund Cluster have deployed their inaugural investments in the company. This robust capital reserve provides a solid foundation for advancing its technological R&D and industrialization efforts.

About`Macera Therapeutics`

Founded in September 2022, Macera Therapeutics is a National Science and Technology-based SME in China, specializing in the research and development of cellular immunotherapy drugs. The company was founded under the leadership of Professor Shen Pingping from the School of Life Sciences at Nanjing University. With over two decades of dedicated research in the macrophage field, Prof. Shen is an internationally recognized authority in this domain. As early as 2020, her core team was recognized by 《Nature Biotechnology》 as a globally pioneering team in CAR-M technology, firmly positioning the company's research capabilities at the forefront of the industry.

Leveraging a top-tier research team and robust capital backing, Macera Therapeutics has deeply focused on the core therapeutic area of CAR-M (Chimeric Antigen Receptor Macrophage), establishing a dual-track R&D pipeline matrix targeting "fibrosis + solid tumors," with multiple core products representing global first-in-class innovations.

Its independently developed in vivo macrophage editing technology effectively enables the universal application of immune cell therapies, significantly reducing clinical treatment costs; its core product, MACF-001, is China's first novel engineered macrophage therapy for liver cirrhosis to enter clinical trials, having successfully completed first-patient enrollment and safety follow-up in 2025. Demonstrating excellent clinical efficacy and with overall R&D progress firmly ranking among the top three globally, the company is poised to become a benchmark enterprise in the global cellular therapy landscape for liver diseases.

References:

Public Information